In a Honduran city, biotechs create gene therapy cocktails to fight aging
By Frankie Fattorini,
Pharmaceutical Technology
| 12. 02. 2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a clinical site in Próspera to study the cognitive and health benefits with its circular RNA therapy in a Phase I trial (NCT07216781), in addition to a site in Austin, Texas, where it is headquartered. Last year, the longevity-focused biotech Unlimited Bio got incorporated in the city. Its CEO Ivan Morgunov told Pharmaceutical Technology that Próspera’s lax regulations foster the company’s lofty goal to create a regimen of gene therapies and other treatments aimed at addressing what he sees as the problem of human ageing.
However, industry experts are not yet convinced. Fellow gene therapy developers question both the scientific plausibility of fighting ageing through combinatorial gene therapies and whether ageing can be pathologised at all. At the same time, it is unknown if such biotechs can gather data acceptable to regulatory agencies like the US Food and Drug Administration...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...